OSLO, Norway, July 1, 2025 /PRNewswire/ — SonoClear AS today announced that the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) has designated the SonoClear® System as a Breakthrough Device for use in intracranial ultrasound procedures.
Regulatory Approval Paves the Way for U.S. Market Launch of Innovative Therapy Targeting Chronic Pain and Neurological Disorders
Electrodes coated with DNA could enable inexpensive tests with a long shelf-life, which could detect many diseases and be deployed in the doctor’s office or at home.
New cutting-edge software developed in Melbourne can help uncover how the most common heart tumor in children forms and changes. And the technology has the potential to further our understanding of other childhood diseases, according to a new study.
Traditional histopathology, crucial for disease diagnosis, relies on chemically staining tissue samples to highlight cellular structures for microscopic examination by pathologists. This labor-intensive “histochemical staining” process is time-consuming, costly, requires chemical reagents, and is destructive to the tissue.